Adding low-dose spironolactone to multidrug regimens for resistant hypertension.
Berecek
Kathleen H
KH
Department of Physiology and Biophysics, University of Alabama at Birmingham, 35294, USA. berecek@uab.edu
Farag
Amal
A
Bahtiyar
Gul
G
Rothman
Jeffery
J
McFarlane
Sammy I
SI
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage*; D013148:Spironolactone / Q000008:administration & dosage*; D013599:Systole / Q000187:drug effects
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone